Introduction: Resistance to colorectal cancer (CRC)
therapies is a significant cause of treatment failure. We used
an in vitro model to identify novel therapeutic targets, explain
mechanisms of carcinogenesis and resistance to therapy, and
ultimately aid patient stratification for therapy.
Methods: A panel of 15 CRC cell lines was profiled by
comparative genomic hybridisation, gene expression profiling,
reverse phase protein array analysis, and chemosensitivity assays
with respect to 5fluorouracil, oxaliplatin, and BEZ235. As proof
of concept, fluorescence in situ hybridization and automated
quantitative protein analysis were employed to investigate a
candidate biomarker in a CRC patient cohort (n=n8).peer-reviewe
